Contrarian Investors: Is Aurora Cannabis (TSX:ACB) Stock a Buy?

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) is down 50% in the past six months. Is this pot stock now oversold?

| More on:
question marks written reminders tickets

Image source: Getty Images

With equity markets trading near all-time highs, contrarian investors are searching for troubled stocks that have fallen out of favour and might offer a shot at some big gains on a turnaround.

Let’s take a look at Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if it deserves to be on your buy list today.

Tough run

Aurora Cannabis trades at $6.50 per share right now, down 50% in the past six months.

The drop is primarily due to a general pullback in the entire cannabis sector, as investors try to digest the fallout from companies running into trouble with regulators for not following the rules.

The absence of profits is also starting to force investors to rethink how much they want to pay for the shares of a marijuana company that continues to burn through cash.

The rapid emergence of the Canadian marijuana industry and pressures to get as much product to market as quickly as possible likely led to some of the bad decisions that have hit the sector in the past year. Namaste, Aphria, and, more recently, CannTrust have all run into trouble for issues ranging from self-dealing to growing plants in unlicensed facilities.

Investors might be wondering if these are isolated incidents or simply the start of more surprises to come from other players. As a result, many might be stepping back from pot stocks.

Regarding Aurora Cannabis, the company is one of the top two players in Canada and has grown significantly through a series of aggressive acquisitions. The recent extension of the slide in the stock price is due to weak results in the latest quarter.

Aurora missed revenue expectations, even after giving the market a heads up last month. In addition, the company pushed out its guidance for reaching profitability to some time in fiscal 2020. Net revenue in the most recent quarter came in at roughly $99 million compared to the $108 million expected by analysts who follow the stock.

Risk

Aurora Cannabis still has a market capitalization of $6.8 billion, which is steep for a company with annualized revenue of about $400 million and no profits. The downward trend in the stock might continue, as investors reset their expectations for the timing of the company’s move to profitability.

Determining the upside potential for earnings growth in the next few years is a challenge, and the market might not be willing to pay such a rich premium.

In addition, investors are not happy that the rollout of the recreational market in Canada has not gone very well, and people are hesitant to make big bets ahead of the launch of the edibles market. If edibles sales don’t go well, another steep leg to the downside could be on the way for Aurora Cannabis and its peers.

Opportunity

The negative sentiment across the industry might actually present an opportunity to get in while the stock is out of favour. There is a chance the edibles market will meet expectations. In that case, we could see cannabis stocks rally in early 2020 the way they did in January of 2019.

Should you buy?

As the marijuana industry matures, Aurora Cannabis is expected to be one of the eventual winners, given its size and its leadership position. If you are a cannabis bull, you might want to start nibbling, but I would probably wait for evidence the pullback has run its course before adding the shares to your portfolio.

There are other ways to play the growth of the cannabis industry without betting on the producers.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »